专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06291466B1 Cholinergic agents in the treatment of presbyopia 失效
标题翻译：胆碱能药物治疗老花眼
公开(公告)号：US06291466B1
公开(公告)日：2001-09-18
申请号：US09126064
申请日：1998-07-30
申请人： Arlene Gwon , Elizabeth WoldeMussie
发明人： Arlene Gwon , Elizabeth WoldeMussie
IPC分类号： A67K31505
CPC分类号： A61K31/695 , A61K31/00 , A61K31/221 , A61K31/27 , A61K31/341 , A61K31/4178 , A61K31/4453 , A61K31/452 , A61K31/551 , A61K31/5513 , Y10S514/912
摘要： A method for increasing or decreasing parasympathetic/cholinergic/ciliary tonic contraction in order to restore the resting portion of the eye and allow normal positive and negative accommodation includes administering to a presbyopic subject an effective amount of a muscarinic agent.
摘要翻译：用于增加或减少副交感神经/胆碱能/睫状肌紧张收缩以恢复眼睛的静息部分并允许正常的阳性和阴性适应的方法包括向老花科对象施用有效量的毒蕈碱药。

2. 发明授权

US06410544B1 Cholinergic agents in the treatment of presbyopia 有权
标题翻译：胆碱能药物治疗老花眼
公开(公告)号：US06410544B1
公开(公告)日：2002-06-25
申请号：US09842299
申请日：2001-04-25
申请人： Arlene Gwon , Elizabeth WoldeMussie
发明人： Arlene Gwon , Elizabeth WoldeMussie
IPC分类号： A61K31505
CPC分类号： A61K31/695 , A61K31/00 , A61K31/221 , A61K31/27 , A61K31/341 , A61K31/4178 , A61K31/4453 , A61K31/452 , A61K31/551 , A61K31/5513 , Y10S514/912
摘要： A method for increasing or decreasing parasympathetic/cholinergic/ciliary tonic contraction in order to restore the resting portion of the eye and allow normal positive and negative accommodation includes administering to a myopic or hyperopic presbyope.
摘要翻译：用于增加或减少副交感神经/胆碱能/睫状肌紧张收缩以恢复眼睛的静息部分并允许正常的阳性和阴性适应的方法包括给予近视或远视的远视。

3. 发明授权

US5559151A Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers 失效
标题翻译：通过施用氯化物通道阻断剂降低哺乳动物眼睛眼内压的方法
公开(公告)号：US5559151A
公开(公告)日：1996-09-24
申请号：US346660
申请日：1994-11-30
申请人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz
发明人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz
IPC分类号： A61K45/00 , A61K31/00 , A61K31/137 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/24 , A61K31/245 , A61K31/26 , A61P27/02 , A61P27/06
CPC分类号： A61K31/00 , A61K31/137 , A61K31/192 , A61K31/196 , A61K31/26 , Y10S514/912 , Y10S514/913
摘要： Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon atoms, that may be derived from a lower alkanol.
摘要翻译：公开了用于治疗哺乳动物眼中的青光眼和/或高眼压症的药物组合物和方法，其通过向哺乳动物眼睛施用本发明的药物组合物，其含有一种或多种具有氯通道阻断活性的化合物作为活性成分。在药物组合物和治疗方法中使用的氯化物通道阻断剂的实例是：其中R是氢或药学上可接受的阳离子，例如，碱金属或碱土金属或季胺; 或R表示酯形成部分，例如。具有至多6个碳原子的低级烷基，其可以衍生自低级链烷醇。

4. 发明授权

US08541426B2 Pharmaceutical compositions and methods of treating dry eye disorders 有权
标题翻译：治疗干眼症的药物组合物和方法
公开(公告)号：US08541426B2
公开(公告)日：2013-09-24
申请号：US12668604
申请日：2008-07-04
申请人： Channing R. Beals , Elizabeth WoldeMussie , Hovhannes John Gukasyan , Jingwen Ma
发明人： Channing R. Beals , Elizabeth WoldeMussie , Hovhannes John Gukasyan , Jingwen Ma
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , A61K9/0048
摘要： Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. Jak3 inhibitors useful for treating eye disorders include the compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.
摘要翻译： Janus激酶-3（“Jak3”）的抑制剂可用于治疗干眼病和其它需要润湿眼睛的疾病。用于治疗眼睛疾病的Jak3抑制剂包括化合物3 - {（3R，4R）-4-甲基-3- [甲基 - （7H-吡咯并[2,3-d]嘧啶-4-基） - 氨基] - 哌啶 -1-基} -3-氧代 - 丙腈。

5. 发明授权

US5521210A Ophthalmic use of muscarinic agonists having increased duration of activity 失效
标题翻译：具有增加活动持续时间的毒蕈碱激动剂的眼科用途
公开(公告)号：US5521210A
公开(公告)日：1996-05-28
申请号：US48829
申请日：1993-04-13
申请人： Elizabeth WoldeMussie , Roger F. Steinert , Guadalupe Ruiz
发明人： Elizabeth WoldeMussie , Roger F. Steinert , Guadalupe Ruiz
IPC分类号： A61K31/40
CPC分类号： A61K31/40 , Y10S514/912 , Y10S514/913
摘要： A method for inducing prolonged pseudoaccommodation includes the instillation of an ophthalmic formulation into an eye for contracting the iris sphincter muscle, but not the ciliary muscle, in order to cause sphincter muscle contraction for a period of greater than about one hour per installation. The method further provides for the stabilization of an implanted intraocular lens immediately after surgery and for reducing glare following radial keratotomy.
摘要翻译：用于诱导长时间假性调节的方法包括将眼用制剂滴入眼睛以将虹膜括约肌肌肉而不是睫状肌收缩，以便每次安装大于约1小时引起括约肌收缩。该方法进一步提供了在手术后立即稳定植入的眼内晶状体，并且用于减小径向角膜切开术后的眩光。

6. 发明授权

US5866605A Method for providing a neuroprotective effect to the mammalian eye by administration of chloride channel blockers 失效
标题翻译：通过施用氯化物通道阻断剂向哺乳动物眼睛提供神经保护作用的方法
公开(公告)号：US5866605A
公开(公告)日：1999-02-02
申请号：US998912
申请日：1997-12-29
申请人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz
发明人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz
IPC分类号： A61K45/00 , A61K31/00 , A61K31/137 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/24 , A61K31/245 , A61K31/26 , A61P27/02 , A61P27/06
CPC分类号： A61K31/00 , A61K31/137 , A61K31/192 , A61K31/196 , A61K31/26 , Y10S514/912 , Y10S514/913
摘要： Pharmaceutical compositions and a method are disclosed for providing neuroprotective effect to the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon 20 atoms, that may be derived from a lower alkanol.
摘要翻译：公开了药物组合物和方法，通过向哺乳动物眼睛施用含有作为活性成分的一种或多种具有氯化物通道阻断活性的化合物的本发明的药物组合物，向哺乳动物眼睛提供神经保护作用。在药物组合物和治疗方法中使用的氯化物通道阻断剂的实例是：其中R是氢或药学上可接受的阳离子，例如，碱金属或碱土金属或季胺; 或R表示酯形成部分，例如。具有至多6个碳原子的低级烷基，其可以衍生自低级链烷醇。

7. 发明授权

US5716952A Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists 失效
公开(公告)号：US5716952A
公开(公告)日：1998-02-10
申请号：US853374
申请日：1992-03-18
申请人： Elizabeth WoldeMussie , Guadalupe Ruiz
发明人： Elizabeth WoldeMussie , Guadalupe Ruiz
IPC分类号： A61K45/00 , A61K31/135 , A61K31/445 , A61K31/55 , A61P27/02 , A61K31/34
CPC分类号： A61K31/55 , A61K31/135 , A61K31/445 , Y10S514/913
摘要： Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more muscarinic antagonist compounds. Examples of muscarinic antagonists utilized in the pharmaceutical composition and method of treatment are: 10H-thieno(3,4-b)(1,5)benzodiazepin-10-one 4,9-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl) (telenzepine); 5,11-dihydro-11�4'-methyl-1'-piperazinyl)-acetyl!-6H-pyrido�2,3-b!�1,4!benzodiazepin-6-one (pirenzepine); racemic 11-��2-(Diethylamino)methyl!-1-piperidinyl!-acetyl!-5,11-dihydro-6H-pyrido�2,3-b!�1,4!benzodiazepin-6-one (AF-DX 116); dextrorotatory 11-��2-(Diethylamino)methyl!-1-piperidinyl!-acetyl!-5,11-dihydro-6H-pyrido�2,3-b!�1,4! benzodiazepin-6-one (AF-DX 250); an ophthalmically acceptable salt of 4-diphenylacetoxy-1,1-dimethyl piperidine (4-DAMP); .alpha.-cyclohexyl, -.alpha.-phenyl-1-piperidinepropanol (trihexyphenidyl); cyclohexanemethanol, .alpha.-phenyl, .alpha.-�3-(1-piperidinyl)-1-propynyl (hexbutinol); 6H-pyrido�2,3-b!�1,4!benzodiazepin-6-one, 11-��4-�4-(diethylamino)butyl!-1-piperidinyl!acetyl!-5,11-dihydro (AQ-RA 741); 11-H-pyrido�2,3-b!�1,4!benzodiazepine-11-carboxamide, N-�2-�2-�(dipropylamino)methyl!-1-piperidinyl!ethyl!-5-, 6-dihydro-6-oxo, monomethanesulfonate (AF-DX 384); 1,8-octanediamine, N,N'-bis�6-��2-methoxyphenyl)methyl!amino!hexyl!-tetrahydrochloride (methoctramine) and naphto�2,3-c!furan-1(3H)-one, 4-2-(1,6-dimethyl-2-piperidinyl)ethenyl!decahydro-3-methyl-, �3S-�3 .alpha., 3a .alpha., 4 .beta.�1E,2(2R*,6S*)!,4a .beta., 8a .alpha., 9a .alpha.!!(himbacine).

8. 发明申请

US20060264442A1 Methods for the treatment of ocular and neurodegenerative conditions in a mammal 审中-公开
标题翻译：用于治疗哺乳动物眼部和神经退行性疾病的方法
公开(公告)号：US20060264442A1
公开(公告)日：2006-11-23
申请号：US11133922
申请日：2005-05-18
申请人： Guadalupe Ruiz , Edwin Padillo , Elizabeth WoldeMussie
发明人： Guadalupe Ruiz , Edwin Padillo , Elizabeth WoldeMussie
IPC分类号： A61K31/517
CPC分类号： A61K31/513 , A61K31/517
摘要： Method for the treatment of conditions including ocular and neurodegenerative conditions in a mammal using a composition which comprises an effective amount of an alpha 1 adrenoreceptor antagonist.
摘要翻译：使用包含有效量的α1肾上腺素受体拮抗剂的组合物治疗哺乳动物使用的眼部和神经变性病症的病症的方法。

9. 发明授权

US6077839A Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists 失效
标题翻译：通过给予γ-氨基丁酸（GABA）激动剂降低哺乳动物眼睛眼内压的方法
公开(公告)号：US6077839A
公开(公告)日：2000-06-20
申请号：US856012
申请日：1992-03-19
申请人： Elizabeth WoldeMussie , Guadalupe Ruiz
发明人： Elizabeth WoldeMussie , Guadalupe Ruiz
IPC分类号： A61K9/08 , A61K31/19 , A61K31/195 , A61K31/42 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/475 , A61K31/55 , A61K45/00 , A61P27/02 , A61P27/06 , A61P43/00 , A61K31/205 , A61K31/385
CPC分类号： A61K31/195 , A61K31/42 , A61K31/44 , A61K31/445 , A61K31/475 , A61K31/55 , Y10S514/913
摘要： Ophthalmic compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by topically administering to the mammalian eye the ophthalmic composition of the invention which contains as the active ingredient one or more gamma aminobutyric acid agonist compounds. Examples of gamma aminobutyric acid agonists utilized in the ophthalmic composition and method of treatment are: gamma aminobutyric acid (GABA), 5-(aminomethyl)-3(2H)-isoxazolone (muscimol), 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) and a pharmaceutically acceptable salt of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, piperidine-4-sulfonic acid and a pharmaceutically acceptable salt of piperidine-4-sulfonic acid, 3-(2H)-isothiazolone, 5-(aminomethyl) (thiomuscimol), 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (diazepam), 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazaepin-2-one (flurazepam) and a pharmaceutically acceptable salt of 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro and 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide (chlordiazepoxide) and a pharmaceutically acceptable salt of 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide.
摘要翻译：公开了用于治疗哺乳动物眼中的青光眼和/或高眼压症的眼科组合物和方法，其通过向哺乳动物眼睛局部施用含有作为活性成分的一种或多种γ-氨基丁酸激动剂化合物的本发明的眼用组合物。用于眼科组合物和治疗方法的γ-氨基丁酸激动剂的实例是：γ-氨基丁酸（GABA），5-（氨基甲基）-3（2H） - 异恶唑酮（麝香草酚），4,5,6,7-四氢异恶唑并[ 5,4-c]吡啶-3-醇（THIP）和4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3-醇的药学上可接受的盐，哌啶-4-磺酸和哌啶-4-磺酸的药学上可接受的盐，3-（2H） - 异噻唑酮，5-（氨基甲基）（硫代假毛醇），7-氯-1,3-二氢-1-甲基-5-苯基-2H- 4-苯并二氮杂-2-酮（地西泮），7-氯-1- [2-（二乙基氨基）乙基] -5-（2-氟苯基）-1,3-二氢-2H-1,4-苯并二氮杂_ 一种（氟西泮）和7-氯-1- [2-（二乙基氨基）乙基] -5-（2-氟苯基）-1,3-二氢和7-氯-N-甲基-5-苯基的药学上可接受的盐 -3H-1,4-苯并二氮杂-2-胺4-氧化物（氯氮烷）和7-氯-N-甲基-5-苯基-3H-1,4-苯并二氮杂-2-胺4-氧化物的药学上可接受的盐。

10. 发明授权

US5925342A Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers 失效
标题翻译：通过施用钾通道阻滞剂降低哺乳动物眼睛眼内压的方法
公开(公告)号：US5925342A
公开(公告)日：1999-07-20
申请号：US891623
申请日：1997-07-09
申请人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz , Kara Kopper , Alison M. Moore
发明人： Joseph S. Adorante , Elizabeth WoldeMussie , Guadalupe Ruiz , Kara Kopper , Alison M. Moore
IPC分类号： A61K31/00 , A61K31/407 , A61K31/475 , A61K31/49 , A61K38/17 , A61K31/74
CPC分类号： A61K31/00 , A61K31/407 , A61K31/475 , A61K31/49 , A61K38/1767 , Y10S514/912
摘要： Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such as charybdotoxin and iberiotoxin.
摘要翻译：公开了药物组合物和方法，用于通过向哺乳动物眼睛施用含有作为活性成分的一种或多种具有钾通道阻断活性的化合物的本发明的药物组合物来治疗哺乳动物眼中的青光眼和/或高眼压症。在药物组合物和治疗方法中使用的钾通道阻滞剂的实例是奎宁，致命的吲哚生物碱，例如Penitrem A和Paspalicine，以及昆虫毒素如charybdotoxin和iberiotoxin。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式